Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - March 14, 2025) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) recently completed an agreement with NX Development Corp., the ...

Rupall faces generic competition in Canada following the expiration of its market exclusivity in January 2025, and Medexus has initiated strategic measures to support the product in this new context.

On Friday, Stifel Canada analysts adjusted their stance on Medexus Pharma (MDP:CN) (OTC: PDDPF), downgrading the stock rating from Buy to Hold and reducing the price target to Cdn$3.45 from the ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Medexus Pharmaceuticals Inc (MEDXF) successfully completed the FDA review process for GRAFAPEX, which holds Orphan Drug Designation, granting at least seven years of regulatory exclusivity.

Medexus Pharmaceuticals has a 52-week low of C$1.47 and a 52-week high of C$5.56. The firm has a market capitalization of C$56.87 million, a price-to-earnings ratio of 12.15 and a beta of 1.96 ...

Medexus Pharmaceuticals Inc. operates as a pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology ...

(MENAFN- Baystreet) 03:51 PM EST - Medexus Pharmaceuticals : Recently completed an agreement with NX Development Corp., the licensor of Medexus's rights to Gleolan® in the United States ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - March 14, 2025) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) recently completed an agreement with NX Development Corp., the licensor of ...